 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"American Diabetes Association 65th Scientific Sessions, San Diego, June 9th-14th 2005: Selected Highlights"Prof. Timothy Davis (biography)
English - 2005-06-17 - 46 minutes
|
 | (25 slides) |
Summary :
In this presentation Prof. Davis covers several topics presented at the ADA's 65th Annual Scientific Sessions.
In a session on late-breaking clinical trials, data were presented on statin therapy in patients with diabetes in the TNT (Treating to New Targets) study, on the efficacy and safety of the PPAR alpha/gamma activator muraglitazar, and on the effects of rimonabant in mostly overweight/obese patients with type 2 diabetes in the RIO (Rimonabant In Obesity) Diabetes trial. Prof. Davis reviews these data and discusses newer therapies such as GLP-1 analogues, DPP4 inhibitors, inhaled insulin, and a new transdermal insulin delivery system.
With regard to chronic complications, data from the DCCT/EDIC studies showed a reduced incidence of CVD events in intensively treated type 1 diabetic subjects compared to the conventionally treated group. Data from the UKPDS showed different variables to be associated with an increased incidence of neuropathy. Also presented were data on erectile dysfunction, foot/leg ulcers and amputations. In the Diabetes Prevention Program, a linear increase in the prevalence of retinopathy was observed after diagnosis of type 2 diabetes.
Prof. Davis discusses novel hypotheses challenging the traditional view of autoimmunity versus insulin resistance in type 1 and type 2 diabetes, respectively, and studies on the prevention/treatment of type 2 diabetes in youth.
The ACHOIS (Australasian Carbohydrate Intolerance Study) showed various benefits due to intensive management of women with GDM, and other data were presented suggesting benefits of metformin therapy in insulin resistant women, in terms of pregnancy outcomes.
Prof. Davis ends the presentation by discussing some topics of general interest, such as new genes for obesity, the effects of IL-6, insulin infusions and acute MI, and a new PPAR drug, metaglidasen.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
- Late-breaking clinical trials
- Update on newer therapies
- New data on chronic complications
- Type 1 vs type 2 diabetes
- Type 2 diabetes in youth
- Glucose intolerance in pregnancy
- Some topics of general interest
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
